Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas
about
Regulation of the Target of Rapamycin and Other Phosphatidylinositol 3-Kinase-Related Kinases by Membrane TargetingNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewInhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingTargeting MYC Dependence by Metabolic Inhibitors in CancerDevelopments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphomaEfficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemiaMYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancersConstitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphomaInhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.Combined loss of the BH3-only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic miceTargeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac ToxicityGlutaminolysis and autophagy in cancerThe SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathwaysDisruption of prostate epithelial differentiation pathways and prostate cancer development.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Ribosomal proteins as novel players in tumorigenesis.BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.Involvement of the cytoplasmic cysteine-238 of CD40 in its up-regulation of CD23 expression and its enhancement of TLR4-triggered responses.Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancerThe dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells.Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines.
P2860
Q26783004-680383F7-1B13-4009-922C-5A9E325FA73BQ27304386-B6DA561D-7461-4F97-9A48-A09B1B28A920Q28468631-0CDA7CB0-EC9D-4C04-8170-AD6BD0DAA106Q33608493-67504AD4-1757-4FB8-A0D0-11865BB1B692Q34039568-3E81F742-73BC-4ECC-929E-8A9FA625446AQ34255861-4366C59B-FAA4-40B4-A170-EE5F3C65E8EAQ34786480-412449BD-245F-4AB5-80B5-BB0A437D016CQ34991267-D52C4F38-9803-43E8-9B4F-D61FEDAE1A7EQ35740025-5E8B8287-62F1-4465-83C6-2096BB4CA130Q35741623-E5AAA14D-8702-4567-B5C8-C87516944D13Q35941499-951DCD43-7FE7-4B46-91E2-7DD145BABF0BQ35999766-A8CCAC5E-CE18-4A66-8783-6865BD5C742AQ36111779-62C5F339-0DDE-423D-9910-63D397793B03Q36846723-E61A407E-7383-45C6-A997-4A86A28A2D37Q37660260-8278B0AF-BA25-41B8-991C-687CB4032707Q37718328-3A300157-5F5C-4894-BE2B-09869A32011EQ38160495-8C7BCFF3-7AA5-4930-A8FF-168981488C21Q38161760-A89E2589-CCF2-4C7E-951A-5EFC9796AE57Q38174514-73D5C5E2-F1B5-4165-B6C2-3E4B31AF42F1Q38799987-7C336F4A-41E0-4D68-8F0A-26B46C3657A4Q38874554-B157A0A2-0F1E-4A1A-952D-71AE850C112DQ38957093-929F58B5-1145-402A-82ED-3D165B093659Q39069931-BBFDF22B-D401-4617-AC06-E086EA2A2D51Q41582917-36F1F44E-E9BA-4FF1-A517-24FB9CFE0666Q42906858-0D097948-ED53-45A1-91A8-D8BD8D10C4ACQ47368952-7FDEF27A-85A8-491C-83F0-CA1585E4A657Q52649710-42BF57DA-0DB7-4629-954E-B829F9DFEC74
P2860
Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Combined inhibition of PI3K-re ...... in MYC-driven B-cell lymphomas
@ast
Combined inhibition of PI3K-re ...... in MYC-driven B-cell lymphomas
@en
type
label
Combined inhibition of PI3K-re ...... in MYC-driven B-cell lymphomas
@ast
Combined inhibition of PI3K-re ...... in MYC-driven B-cell lymphomas
@en
prefLabel
Combined inhibition of PI3K-re ...... in MYC-driven B-cell lymphomas
@ast
Combined inhibition of PI3K-re ...... in MYC-driven B-cell lymphomas
@en
P2093
P2860
P50
P1433
P1476
Combined inhibition of PI3K-re ...... in MYC-driven B-cell lymphomas
@en
P2093
Adele J Baker
Andrea Newbold
Benjamin P Martin
Jennifer R Devlin
Katherine M Hannan
Maurice Reimann
Meaghan Wall
Michael N Hall
Rachael Ralli
Richard B Pearson
P2860
P304
P356
10.1182/BLOOD-2012-08-446096
P407
P577
2013-02-12T00:00:00Z